14/09/2020 (Agence Europe) – The pharmaceutical group AstraZeneca announced on Saturday 12 September that it had received the green light from the British regulatory authority to resume clinical trials on the candidate vaccine it is developing with the University of Oxford. Three days earlier, the group had announced the interruption of these tests following the unexplained illness of one of the participants (see EUROPE B12556A7). The independent committee set up to look into the case...